Orris
attachment
attachment

What are its usage and what is the mechanism of action and what are the contraindications

Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Here is a complete breakdown of Budetrol 200 (Formoterol Fumarate Dihydrate + Budesonide Inhalation):

Budetrol 200 - Formoterol + Budesonide Inhaler

This is a fixed-dose combination metered-dose inhaler (MDI) containing:
  • Budesonide 200 mcg - an inhaled corticosteroid (ICS)
  • Formoterol Fumarate Dihydrate 6 mcg - a long-acting beta-2 agonist (LABA)

Indications / Uses

  1. Asthma (moderate to severe persistent) - the primary indication. When asthma is inadequately controlled by an ICS alone, adding a LABA is more effective than doubling the ICS dose.
  2. COPD - maintenance therapy for patients with frequent exacerbations (especially those with blood eosinophils >300 cells/µL).
  3. SMART strategy (Single Maintenance And Reliever Therapy) - because formoterol has a rapid onset (similar to salbutamol), this combination can be used both as a daily scheduled controller AND as an as-needed reliever inhaler, replacing a separate rescue inhaler. This has been part of US and international guidelines since 2020.
  • Katzung's Basic and Clinical Pharmacology, 16th Ed.
  • Goldman-Cecil Medicine

Mechanism of Action

Formoterol (LABA component)

  • Selectively activates beta-2 adrenergic receptors on bronchial smooth muscle
  • Receptor activation stimulates adenylyl cyclase, increasing intracellular cAMP
  • Elevated cAMP activates protein kinase A (PKA), which phosphorylates myosin light-chain kinase, reducing smooth muscle tone
  • Result: bronchodilation - relaxation of airway smooth muscle
  • Onset is rapid (~1-3 minutes), distinguishing formoterol from salmeterol and allowing it to double as a reliever
  • Duration: ~12 hours (long-acting)
  • Also inhibits mast cell mediator release and reduces microvascular leakage

Budesonide (ICS component)

  • Binds intracellular glucocorticoid receptors (GR) in airway cells
  • The drug-receptor complex translocates to the nucleus and binds to glucocorticoid response elements (GREs)
  • This upregulates anti-inflammatory genes (lipocortin-1, beta-2 receptors) and downregulates pro-inflammatory genes (cytokines IL-4, IL-5, IL-13; chemokines; COX-2)
  • Reduces eosinophilic and lymphocytic airway inflammation, decreases mucus secretion, and reduces airway hyperresponsiveness
  • Does NOT cause acute bronchodilation - it acts as a long-term controller/anti-inflammatory

Synergy of the combination

Budesonide upregulates beta-2 receptor expression, preventing the desensitization (downregulation) that would otherwise occur with prolonged formoterol use. Formoterol, in turn, activates the GR, enhancing budesonide's anti-inflammatory effect at the receptor level.
  • Katzung's Basic and Clinical Pharmacology, 16th Ed.
  • Goodman & Gilman's The Pharmacological Basis of Therapeutics

Contraindications

Absolute Contraindications

ContraindicationReason
Hypersensitivity to budesonide, formoterol, or any excipientAnaphylaxis risk
Acute severe bronchospasm / status asthmaticusThis is not a rescue inhaler in an emergency; use SABA (salbutamol) instead
Use of formoterol as monotherapy for asthma (without ICS)LABAs used alone increase risk of fatal/near-fatal asthma attacks (FDA Black Box Warning)

Relative Contraindications / Cautions

SituationConcern
Untreated active pulmonary tuberculosis, fungal, or viral respiratory infectionsICS can worsen infections by local immunosuppression
Severe cardiovascular disease (arrhythmias, ischemic heart disease)Formoterol can cause tachycardia, QTc prolongation, hypokalemia
ThyrotoxicosisBeta-agonist effects are amplified
HypokalemiaFormoterol can worsen it, especially with diuretics or theophylline
Diabetes mellitusCorticosteroids raise blood glucose; beta-agonists also cause transient hyperglycemia
OsteoporosisLong-term ICS increases bone loss risk
Children under 6 yearsSafety not established for this formulation
PregnancyUse only if benefit outweighs risk; budesonide is the preferred ICS in pregnancy
Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, itraconazole)Increase systemic budesonide exposure significantly; avoid co-administration

Key Adverse Effects to Know

  • Local (inhaled): Oropharyngeal candidiasis, dysphonia (hoarse voice), cough - rinse mouth after each use
  • Systemic (with high doses): Adrenal suppression, growth retardation in children, osteoporosis, cataracts, glaucoma, metabolic disturbances (glucose, insulin)
  • Formoterol-related: Tachycardia, palpitations, tremor, headache, hypokalemia
  • Goodman & Gilman's, Table 44-4
  • The Harriet Lane Handbook, 23rd Ed.
Important clinical note: Never use this inhaler as the sole reliever in a life-threatening asthma attack. A short-acting beta-agonist (salbutamol/albuterol) must always be available for acute rescue, unless following the formal SMART protocol under physician supervision.
This is a shared conversation. Sign in to Orris to start your own chat.